Compare Alcon AG (ALC) vs Crocs, Inc. (CROX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Crocs, Inc. — how do they compare? Alcon AG trades at $66.84 (market cap $32.69B), while Crocs, Inc. trades at $121.97 (market cap $6.19B). The key difference: Alcon AG is far larger — about 5.3× Crocs, Inc.'s market cap, and Alcon AG pays a 0.54% dividend while Crocs, Inc. pays none. Which is the better fit depends on your goals.
| ALC | CROX | |
|---|---|---|
Market Cap | $32.69B | $6.19B |
Sector | Health | Consumer Staples |
52-Week High | $92.22 | $127.77 |
52-Week Low | $62.02 | $73.39 |
Enterprise Value | $36.28B | $7.78B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Crocs (CROX) trades at $124.55, down 0.58% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue of $4.04B for 2025 but posted a net loss of $81.20M, with negative profit margins. Recent earnings have consistently beaten expectations, and analyst sentiment remains positive with a 51.35% buy rating and consensus price target of $131.75. News highlights include marketing initiatives like TikTok microdramas and expansion in Asian markets.
The outlook for CROX is mixed: strong brand momentum and earnings beats support upside potential, but profitability concerns and negative net income margins pose risks. Investors should weigh growth initiatives against margin pressures and competitive dynamics in the apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →
